vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and MIND CTI LTD (MNDO). Click either name above to swap in a different company.
MIND CTI LTD is the larger business by last-quarter revenue ($4.9M vs $3.9M, roughly 1.3× Opus Genetics, Inc.). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -45.1%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
MIND CTI Ltd. is a global provider of billing and customer care solutions and messaging services for voice, data, video and content services. Headquartered in Yokneam, Israel; the company also has offices in the United States of America, Iaşi in Romania and in Germany.
IRD vs MNDO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.9M |
| Net Profit | — | $950.0K |
| Gross Margin | — | 55.4% |
| Operating Margin | — | 16.5% |
| Net Margin | — | 19.4% |
| Revenue YoY | -10.2% | — |
| Net Profit YoY | 53.0% | — |
| EPS (diluted) | — | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.9M | ||
| Q3 25 | $3.1M | $16.2M | ||
| Q2 25 | $2.9M | $11.0M | ||
| Q1 25 | $4.4M | — | ||
| Q4 24 | $4.3M | $5.2M | ||
| Q3 24 | $3.9M | $16.0M | ||
| Q2 24 | $1.1M | $10.7M | ||
| Q1 24 | $1.7M | — |
| Q4 25 | — | $950.0K | ||
| Q3 25 | $-17.5M | $3.4M | ||
| Q2 25 | $-7.4M | $2.5M | ||
| Q1 25 | $-8.2M | — | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-7.5M | $3.7M | ||
| Q2 24 | $-7.8M | $2.5M | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 48.3% | ||
| Q2 25 | — | 50.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 55.6% | ||
| Q3 24 | — | 50.6% | ||
| Q2 24 | — | 50.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 16.5% | ||
| Q3 25 | -269.9% | 18.8% | ||
| Q2 25 | -309.0% | 21.0% | ||
| Q1 25 | -227.2% | — | ||
| Q4 24 | — | 25.4% | ||
| Q3 24 | -207.1% | 22.5% | ||
| Q2 24 | -748.9% | 22.2% | ||
| Q1 24 | -450.5% | — |
| Q4 25 | — | 19.4% | ||
| Q3 25 | -566.9% | 20.9% | ||
| Q2 25 | -257.5% | 22.3% | ||
| Q1 25 | -187.5% | — | ||
| Q4 24 | — | 23.8% | ||
| Q3 24 | -194.6% | 23.3% | ||
| Q2 24 | -698.3% | 23.1% | ||
| Q1 24 | -415.3% | — |
| Q4 25 | — | $0.05 | ||
| Q3 25 | $-0.25 | $0.16 | ||
| Q2 25 | $-0.12 | $0.12 | ||
| Q1 25 | $-0.24 | — | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | $-0.29 | $0.18 | ||
| Q2 24 | $-0.30 | $0.12 | ||
| Q1 24 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $8.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $23.0M |
| Total Assets | $50.2M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $8.3M | ||
| Q3 25 | $30.8M | $4.5M | ||
| Q2 25 | $32.4M | $4.5M | ||
| Q1 25 | $41.8M | — | ||
| Q4 24 | $30.3M | $4.6M | ||
| Q3 24 | $36.6M | $3.0M | ||
| Q2 24 | $41.4M | $3.0M | ||
| Q1 24 | $47.2M | — |
| Q4 25 | $15.3M | $23.0M | ||
| Q3 25 | $6.0M | $24.3M | ||
| Q2 25 | $17.5M | $24.3M | ||
| Q1 25 | $5.1M | — | ||
| Q4 24 | $6.7M | $24.3M | ||
| Q3 24 | $34.3M | $24.5M | ||
| Q2 24 | $40.6M | $24.5M | ||
| Q1 24 | $46.1M | — |
| Q4 25 | $50.2M | $30.2M | ||
| Q3 25 | $36.1M | $30.7M | ||
| Q2 25 | $38.7M | $30.7M | ||
| Q1 25 | $48.2M | — | ||
| Q4 24 | $36.9M | $30.7M | ||
| Q3 24 | $40.4M | $31.6M | ||
| Q2 24 | $44.8M | $31.6M | ||
| Q1 24 | $51.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $4.0M |
| Free Cash FlowOCF − Capex | — | $4.0M |
| FCF MarginFCF / Revenue | — | 81.0% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 4.20× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $4.0M | ||
| Q3 25 | $-6.2M | $3.8M | ||
| Q2 25 | $-10.3M | $2.9M | ||
| Q1 25 | $-9.0M | — | ||
| Q4 24 | $-25.6M | $4.1M | ||
| Q3 24 | $-5.1M | $3.4M | ||
| Q2 24 | $-7.3M | $2.4M | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $3.8M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.1M | ||
| Q3 24 | — | $3.3M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | — |
| Q4 25 | — | 81.0% | ||
| Q3 25 | — | 23.4% | ||
| Q2 25 | — | 25.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 22.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.32× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
